http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 31 Dec 2025 06:01:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Dec+24/25792309.html si-local-file:///var/storage/secattach/20251231/25792309.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Dec+24/25792309.html Wed, 31 Dec 2025 06:01:00 -0500 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Dec+24/25792309.html si-local-file:///var/storage/secattach/20251231/25792309.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Dec+24/25792309.html Wed, 31 Dec 2025 06:01:00 -0500 EMMA O.05242772 http://www.streetinsider.com/Corporate+News/Emmaus+Life+Sciences+grants+North+American+license+for+Endari+to+NeoImmuneTech/25791308.html <p>Emmaus Life Sciences Inc. (OTCQB: EMMA) entered into a license and exclusive distribution agreement with NeoImmuneTech Inc. for the sickle cell disease treatment Endari in North America, according to a company statement.</p><p>Under the agreement, Emmaus granted NeoImmuneTech exclusive rights to market, sell and distribute Endari, a prescription-grade L-glutamine oral powder, and any generic equivalents for sickle cell disease in the United States, its territories, and Canada. In exchange, Emmaus will receive an upfront payment and royalties on product sales.</p><p>The agreement's effective date depends on NeoImmuneTech obtaining necessary regulatory approvals and licensing to sell and distribute the products, along with other http://www.streetinsider.com/Corporate+News/Emmaus+Life+Sciences+grants+North+American+license+for+Endari+to+NeoImmuneTech/25791308.html Tue, 30 Dec 2025 16:30:38 -0500 EMMA http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921